SCHIZOPHRENIA 1 (Disorder)
15
4
5
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (15)
Multi-target TMS for Schizophrenia Negative Symptoms
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
Efficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders.
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Online Intervention To Improve Motivation
Mindfulness-Based Yoga in Schizophrenia
Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways
Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders
Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia
Cognitive Rehabilitation With Immersive Virtual Reality (IVR) in Schizophrenia: a Pilot Randomized Waiting List Controlled Feasibility Study
PS-Trauma - Development of Trauma Treatment for Patients With Co-morbid Psychotic Disorders and Traumas
Behavioral Impact and Neural Correlates of Network-based Brain Stimulation in Schizophrenia
The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
Disorders of the Sense of Self and Physical Activity
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients